MAINZ / LONDON (IT BOLTWISE) – BioNTech is planning a strategic acquisition of CureVac to accelerate the development of mRNA-based cancer immunotherapies. CureVac shareholders will vote on the terms of the acquisition on November 25, 2025. This merger could significantly advance BioNTech’s oncology strategy.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
BioNTech, a leader in mRNA technology, has launched a public exchange offer for all outstanding shares of CureVac. This offering, which began on October 22, 2025 and ends on December 3, 2025, aims to bring the two mRNA pioneers together. The planned acquisition is based on a purchase agreement dated June 12, 2025 and is intended to accelerate the development of innovative, mRNA-based cancer immunotherapies.
CureVac shareholders face a crucial vote on November 25, 2025, where they will decide the terms of the acquisition. For each CureVac share, shareholders will receive BioNTech American Depositary Shares (ADSs) worth approximately $5.46. This transaction is considered a milestone in the implementation of BioNTech’s oncology strategy as it combines the complementary competencies and technologies of both companies.
The two companies’ share prices have performed differently recently. While BioNTech shares fell by 1.42 percent to $95.59 on the NASDAQ, CureVac shares recorded an increase of 47.51 percent despite a decline of 1.76 percent over the course of the year. Whether the upcoming decision by CureVac shareholders will serve as a catalyst for a change in course remains to be seen.
BioNTech’s full acquisition of CureVac could significantly accelerate the development of mRNA-based therapies. By combining their resources and technologies, both companies could strengthen their position in the field of cancer immunotherapy and bring new therapeutic approaches to market more quickly. However, the approval of CureVac shareholders is crucial for this strategic merger to come about.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “BioNTech plans strategic takeover of CureVac”.